

Senate Bill 486 Evaluation Team
CONSUMER REPORT CARD



SUMMARY:

The legislatively mandated deadline for report submission was July 1, 2012. There were 31 plans submitted as of July 20th to the State of California which posted them on their website for public consumption. These plans were read and graded by a 9-person evaluation team, scoring each plan based on published consumer criteria. There were:

- 5 "A" grade plans;
- 1 "B" grade plans;
- 1 "C" grade plans;
- 1 "D" grade plan;
- **20 "F" grade plans;**
- 2 "Honorable Mentions"
- 3 TBD grades.

- NOTE: At least thirteen manufacturers resubmitted their 2010 or their 2011 plans verbatim and those are indicated with an asterisk (*).

- NOTE: At least eight manufacturers are in VIOLATION of state law by not submitting a plan to the State at all and therefore earning an "F/Incomplete" grade.

<u>Manufacturer</u>	<u>Score</u>	<u>Grade</u>
Abbott Laboratories*	94	A
Amgen	90	A
Amylin*	18	F
Baxter*	2	F
Bayer*	21	F
Biogen Idec	80	B
CSL Behring*	2	F
Dr. Reddy's Lab	9	F
Eisai*	62	D
Eli Lilly & Co.*	13	F
EMD Serono	93	A
Genentech/Roche*	46	F
InterMune	13	F
Janssen Biotech, Inc./ Johnson & Johnson	94	A
JHP Pharmaceuticals	3	F
Kadmon Pharmaceuticals	45	F
Merck & Co.*(Incl. Schering)	32	F
Novartis*	4	F
Perrigo	5	F
Pfizer*	26	F
Salix	3	F
Sandoz	3	F
Sanofi-Aventis*	47	F
Shire HGT	70	C
Teva Biologics*	17	F
Teva Neuroscience*	22	F
UCB Inc.*	94	A
ViroPharma	11	F

HONORABLE MENTION:

- **BD (Becton, Dickinson and Co.)**
- **Waste Management, Inc.**

Although they weren't subject to SB 486, they submitted a plan and earned an **honorable mention** from the SB 486 Evaluation Committee.

2012

The following drug manufactures earned an automatic F grade based on the incomplete nature of their reports. Those manufacturers are:

IN VIOLATION OF STATE LAW DUE TO THE FACT THAT THEY **DID NOT SUBMIT** ANY PLANS TO THE STATE.

<u>Manufacturer</u>	<u>Grade</u>
Biovitrium (3 rd year in a row of non-compliance)	F/ Incomplete
Dey Pharma (History of late submissions: Submitted July 10, 2011. Submitted August 18, 2010)	F/ Incomplete
Ferring	F/ Incomplete
Fresenius Medical Care	F/ Incomplete
Ipsen (History of late submissions: Submitted September 1, 2011. Did not submit a plan at all in 2010.)	F/ Incomplete
Novo Nordisk (2011 Grade: F, 2010 Grade: F)	F/ Incomplete
Questcor Pharmaceuticals (3rd year in a row of non-compliance)	F/Incomplete

The following manufacturers' grades are still being evaluated and calculated by the SB 486 Evaluation Team:

<u>Manufacturer</u>	<u>Grade</u>
Bristol Meyers Squibb	TBD
GlaxoSmithKline	TBD
Grifols	TBD